268 related articles for article (PubMed ID: 1376332)
1. Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface.
Rosenfeld SJ; Yoshimoto K; Kajigaya S; Anderson S; Young NS; Field A; Warrener P; Bansal G; Collett MS
J Clin Invest; 1992 Jun; 89(6):2023-9. PubMed ID: 1376332
[TBL] [Abstract][Full Text] [Related]
2. Most of the VP1 unique region of B19 parvovirus is on the capsid surface.
Kawase M; Momoeda M; Young NS; Kajigaya S
Virology; 1995 Aug; 211(2):359-66. PubMed ID: 7544049
[TBL] [Abstract][Full Text] [Related]
3. Subunit interaction in B19 parvovirus empty capsids.
Rosenfeld SJ; Young NS; Alling D; Ayub J; Saxinger C
Arch Virol; 1994; 136(1-2):9-18. PubMed ID: 7516147
[TBL] [Abstract][Full Text] [Related]
4. T-helper cell-mediated interferon-gamma, interleukin-10 and proliferation responses to a candidate recombinant vaccine for human parvovirus B19.
Franssila R; Hedman K
Vaccine; 2004 Sep; 22(27-28):3809-15. PubMed ID: 15315862
[TBL] [Abstract][Full Text] [Related]
5. Chimeric parvovirus B19 capsids for the presentation of foreign epitopes.
Brown CS; Welling-Wester S; Feijlbrief M; Van Lent JW; Spaan WJ
Virology; 1994 Feb; 198(2):477-88. PubMed ID: 7507280
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions.
Saikawa T; Anderson S; Momoeda M; Kajigaya S; Young NS
J Virol; 1993 Jun; 67(6):3004-9. PubMed ID: 7684458
[TBL] [Abstract][Full Text] [Related]
7. Conformational changes in the VP1-unique region of native human parvovirus B19 lead to exposure of internal sequences that play a role in virus neutralization and infectivity.
Ros C; Gerber M; Kempf C
J Virol; 2006 Dec; 80(24):12017-24. PubMed ID: 17020940
[TBL] [Abstract][Full Text] [Related]
8. Candidate recombinant vaccine for human B19 parvovirus.
Bansal GP; Hatfield JA; Dunn FE; Kramer AA; Brady F; Riggin CH; Collett MS; Yoshimoto K; Kajigaya S; Young NS
J Infect Dis; 1993 May; 167(5):1034-44. PubMed ID: 8486937
[TBL] [Abstract][Full Text] [Related]
9. Purification and analysis of polyhistidine-tagged human parvovirus B19 VP1 and VP2 expressed in insect cells.
Michel PO; Mäkelä AR; Korhonen E; Toivola J; Hedman L; Söderlund-Venermo M; Hedman K; Oker-Blom C
J Virol Methods; 2008 Sep; 152(1-2):1-5. PubMed ID: 18598721
[TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase-polymerase chain reaction-based assay.
Bostic JR; Brown KE; Young NS; Koenig S
J Infect Dis; 1999 Mar; 179(3):619-26. PubMed ID: 9952368
[TBL] [Abstract][Full Text] [Related]
11. B cell memory is directed toward conformational epitopes of parvovirus B19 capsid proteins and the unique region of VP1.
Corcoran A; Mahon BP; Doyle S
J Infect Dis; 2004 May; 189(10):1873-80. PubMed ID: 15122524
[TBL] [Abstract][Full Text] [Related]
12. Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions.
Kajigaya S; Fujii H; Field A; Anderson S; Rosenfeld S; Anderson LJ; Shimada T; Young NS
Proc Natl Acad Sci U S A; 1991 Jun; 88(11):4646-50. PubMed ID: 1711206
[TBL] [Abstract][Full Text] [Related]
13. CD4(+) T-cell responses against the VP1-unique region in individuals with recent and persistent parvovirus B19 infection.
Lindner J; Barabas S; Saar K; Altmann D; Pfister A; Fleck M; Deml L; Modrow S
J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):356-61. PubMed ID: 16316401
[TBL] [Abstract][Full Text] [Related]
14. Detection of parvovirus B19 NS1-specific antibodies by ELISA and western blotting employing recombinant NS1 protein as antigen.
Heegaard ED; Rasksen CJ; Christensen J
J Med Virol; 2002 Jul; 67(3):375-83. PubMed ID: 12116031
[TBL] [Abstract][Full Text] [Related]
15. Molecular and structural characterization of fluorescent human parvovirus B19 virus-like particles.
Gilbert L; Toivola J; White D; Ihalainen T; Smith W; Lindholm L; Vuento M; Oker-Blom C
Biochem Biophys Res Commun; 2005 Jun; 331(2):527-35. PubMed ID: 15850791
[TBL] [Abstract][Full Text] [Related]
16. Controlled conformational transitions in the MVM virion expose the VP1 N-terminus and viral genome without particle disassembly.
Cotmore SF; D'abramo AM; Ticknor CM; Tattersall P
Virology; 1999 Feb; 254(1):169-81. PubMed ID: 9927584
[TBL] [Abstract][Full Text] [Related]
17. Parvovirus particles as platforms for protein presentation.
Miyamura K; Kajigaya S; Momoeda M; Smith-Gill SJ; Young NS
Proc Natl Acad Sci U S A; 1994 Aug; 91(18):8507-11. PubMed ID: 8078912
[TBL] [Abstract][Full Text] [Related]
18. Parvovirus B19 VP2-proteins produced in Saccharomyces cerevisiae: comparison with VP2-particles produced by baculovirus-derived vectors.
Lowin T; Raab U; Schroeder J; Franssila R; Modrow S
J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):348-52. PubMed ID: 16316399
[TBL] [Abstract][Full Text] [Related]
19. Antibody response to B19 parvovirus VP1 and VP2 linear epitopes in patients with haemophilic arthritis.
Azzi A; Manaresi E; Zakrzewska K; DeSantis R; Musiani M; Zerbini M
J Med Virol; 2004 Apr; 72(4):679-82. PubMed ID: 14981773
[TBL] [Abstract][Full Text] [Related]
20. Formation of empty B19 parvovirus capsids by the truncated minor capsid protein.
Wong S; Momoeda M; Field A; Kajigaya S; Young NS
J Virol; 1994 Jul; 68(7):4690-4. PubMed ID: 8207846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
